AVROBIO, Inc. (AVRO)
(Delayed Data from NSDQ)
$19.01 USD
+0.48 (2.59%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.01 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.01 USD
+0.48 (2.59%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.01 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
by Zacks Equity Research
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
by Zacks Equity Research
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn
by Zacks Equity Research
bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study
by Zacks Equity Research
Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.
Theravance's (TBPH) Hypotension Study Misses Primary Goal
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now
by Zacks Equity Research
AVROBIO, Inc. (AVRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks
by Zacks Equity Research
AVROBIO, Inc. (AVRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?
by Zacks Equity Research
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.
AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVROBIO, Inc. (AVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.
5 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.
AVROBIO Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AVROBIO has been struggling lately, but the selling pressure may be coming to an end soon
Why Earnings Season Could Be Great for AVROBIO (AVRO)
by Zacks Equity Research
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is AVROBIO (AVRO) Stock a Solid Choice Right Now?
by Zacks Equity Research
AVROBIO (AVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVROBIO, Inc. (AVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVROBIO, Inc. (AVRO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AVROBIO, Inc. (AVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).